Ac­celeron res­ur­rects block­buster hopes for so­tater­cept with pos­i­tive PhII — and shares rock­et up

Ac­celeron $XL­RN says that its first ma­jor tri­al read­out of 2020 is a suc­cess.

In a Phase II study of 106 pa­tients with pul­monary ar­te­r­i­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.